Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock are down 18% to $142.70 in Thursday midday trading, unwinding a meaningful piece of Wednesday’s historic 177% rally. The reversal follows a Phase 3 win for Moderna’s personalized cancer vaccine, a result that repriced Moderna stock so violently in one session that a retrace looked close to inevitable.
BioNTech (NASDAQ:BNTX) stock is falling 4% to $108.39 as the German mRNA developer hands back part of its own read-across rally. BioNTech shares had entered Thursday up 19% year to date (YTD) on enthusiasm around the broader mRNA oncology platform.
Merck (NYSE:MRK) stock is slipping 1% to $150.63, a barely perceptible move for the pharma giant despite co-owning the same pivotal trial. Merck shares were still up 47% YTD heading into Thursday’s session.
The iShares Biotechnology ETF (NASDAQ:IBB) is down 2% to $213.64, while the Invesco QQQ Trust (NASDAQ:QQQ) is down 0.5% to $712.41. Biotech is taking the heavier hit today, and Moderna sits inside IBB as a holding, so an 18% decline in a single large constituent pulls the fund down with it.
Cancer Vaccine Win Sparks a Two-Day Roundtrip
Moderna and Merck announced that intismeran, their personalized mRNA cancer vaccine, hit its primary endpoint in a Phase 3 trial. The readout showed a meaningful reduction in melanoma recurrence in patients whose tumors had already been surgically removed.
The combination arm paired intismeran with Merck’s Keytruda against Keytruda alone. Patients on the combination lived meaningfully longer without their cancer returning or spreading, validating years of Phase 2 signals previously reported at ASCO 2026.
Why the Rally Reversed So Hard
JPMorgan’s Jessica Fye framed the setup on Moderna stock bluntly, writing that the firm sees “success in adj melanoma as priced in with the stock sitting at ~$25bn market cap prior to the news,” and that “we see the read-across to other indications as critical.” That framing captures why the Moderna trade is giving so much back today.
Bank of America’s Alec Stranahan struck a more constructive tone, calling the result “a watershed moment for Moderna, in our view, effectively allowing the company to diversify away from infectious disease and potentially easing persistent capital overhangs.” Citigroup’s Geoff Meacham cautioned that full validation depends on the complete dataset, potentially due at the ESMO conference in Madrid running October 23 to 27.
Same Trial, Very Different Materiality
The split between Moderna and Merck shares is a clean way to read Thursday’s tape. Moderna carries a market cap of $56.18 billion, and a Phase 3 adjuvant melanoma win reshapes what Moderna is as a business. It hands the company a credible oncology franchise on top of its existing infectious-disease base.
Merck carries a market cap of $371.63 billion with Keytruda already anchoring the company’s oncology portfolio. The same trial result barely registers in Merck stock because the incremental economics are small relative to a Keytruda franchise already generating billions of dollars per quarter across a long list of approved indications.
BioNTech is running its own individualized mRNA cancer immunotherapy, autogene cevumeran, in partnership with Genentech, in adjuvant colorectal and pancreatic settings. BioNTech shares rallied earlier in the week on the platform read-across for mRNA oncology, and BioNTech stock is now handing some of that enthusiasm back. Readers interested in the wider pharma tape can see our prior coverage on which drugmaker stock has dominated in 2026.
What to Watch Next
The unresolved question is whether the melanoma result reads across to other tumor types, since the full Moderna dataset has not been presented publicly yet. Traders can watch for the complete data drop at ESMO in Madrid in late October, the next scheduled catalyst that could either confirm or complicate the bull case on Moderna stock.
Position sizing on Moderna stock matters more than direction here. The single-session round trip shows how narrow the tape can get around one readout, and a moderate weighting keeps a portfolio’s exposure to the next data point manageable while the tumor-type read-across question on Moderna’s platform stays open.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks